Läs mer
Tocris BioScience™ CX-4945
Beskrivning
CX-4945 can be used, in combination with other small molecules, in fast chemical reprogramming protocols for the induction of human somatic cells and highly efficient generation of pluripotent stem cells (hCiPS) in a minimum of 16 days with robust repeatability and reliability.
CX-4945 has antiproliferative effects in vitro as it attenuates PI3K/Akt signalling, causes cell-cycle arrest and selectively induces apoptosis in cancer cells. In models of angiogenesis, CX-4945 inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1α) transcription in cancer cells.
In vivo, CX-4945 displays robust antitumor activity with concomitant reduction of the mechanism-based biomarker phospho-p21 (T145) (murine xenograft model). CX-4945 is orally bioavailable.
Specifikationer
Specifikationer
| Kemiskt namn eller material | Sodium 5-[(3-Chlorophenyl)amino]benzo[c]-2,6-naphthyridine-8-carboxylate |
| CAS | 1309357-15-0 |
| Kvantitet | 10 mg |
| Mål | Casein Kinase 2 Inhibitors |
| Molekylformel | C19H11ClN3O2Na |
| Renhet | 98% |
Genom att klicka på Skicka bekräftar du att du kan bli kontaktad av Fisher Scientific angående feedbacken du har lämnat i detta formulär. Vi kommer inte att dela din information för andra ändamål. All kontaktinformation som tillhandahålls ska också underhållas i enlighet med vår Sekretesspolicy.